PATENT CLAIM ANALYSIS

Application Number: 16112304
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["424", "133100"]

Abstract:
The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.

Claim (Index 19):
The method of any one of the preceding claims wherein the chimeric anti-endoglin antibody and the VEGF antagonist are present in the same composition.

Metadata:
- Claim Count in Document: 133.0
- Percentile: 96.0
- Lexical Diversity: 2.29167
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13485702', '14054446', '15337113', '14838006', '12751907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7966425644562869
- 35 USC 102 Novelty (BERT): 0.5439566594269718
- Combined Prediction Score: 0.7713739739533554
- Mean Citation Score: 385.918738
- Max Citation Score: 422.3443
- Similarity Product: 251.7387329439401

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test